San Diego, USA, October 10th, 2023 – CELLINK, a leading global provider of bioprinting technologies, and the University of California, San Diego (UCSD), a world-renowned research institution, are pleased to announce their partnership to establish a 3D bioprinting Centre of Excellence. This partnership aims to facilitate the utilization of advanced bioprinting technologies and promote cutting-edge research in the fields of drug discovery, cancer research, and tissue engineering.
The Centre of Excellence will house state-of-the-art CELLINK bioprinters, including the flagship BIO X6 and BIONOVA X bioprinters, a range of bioinks and the leading bioprinting software offerings. The facility will be led by Prof. Shaochen Chen, a pioneer and expert in 3D printing and biofabrication, who has published extensively on bioprinting techniques for tissue engineering and regenerative medicine. The Centre of Excellence will provide researchers at UCSD and beyond with increased access to CELLINK bioprinting technologies and support their efforts to develop innovative solutions to address some of the most pressing challenges in healthcare.
Cecilia Edebo, CEO of CELLINK, said, “We are thrilled to partner with the University of California, San Diego to establish a Centre of Excellence that will further advance the development of 3D bioprinting technologies. Through this partnership, we aim to provide researchers with the tools and expertise needed to accelerate their research efforts in developing liver models for drug discovery, accurate cancer models for precision medicine, and exploring the potential of combining light and extrusion bioprinting modalities to advance tissue engineering.”
Prof. Shaochen Chen added, “The Centre of Excellence will enable us to bring together researchers from diverse backgrounds to collaborate on developing novel bioprinting approaches for tissue engineering and regenerative medicine. This partnership with CELLINK will provide us with access to the most advanced bioprinting technologies, and we look forward to leveraging these tools to make significant strides in our research efforts.”
The establishment of this Centre of Excellence marks a significant milestone for CELLINK and UCSD as they continue to push the boundaries of 3D bioprinting and pave the way for groundbreaking research in the field of biotechnology.
For more information on the Centre of Excellence, please visit CELLINK’s website or contact them directly.
For further information, please contact:
Avijit Minocha, Head of Marketing, CELLINK
Phone: +1 617 637 5372
CELLINK is enabling the future of health as part of BICO, the world’s leading bioconvergence company. When CELLINK released the first universal bioink in 2016 and subsequently launched the world’s first affordable 3D bioprinter it democratized the cost of entry for researchers around the world and played a major role opening up the field of 3D bioprinting. Today, the company’s best-in-class bioinks, bioprinters, software and services have been cited in over 1000 publications and are trusted by more than 1,600 academic, pharmaceutical and industrial labs. With a comprehensive portfolio of world-class 3D bioprinters and bioinks CELLINK’s technology enables the printing of human tissues and organs, which enable faster and more accurate models for drug development, while replacing animal experiments and paving the way to save lives by reducing organ rejection and potentially solve the problem with lack of donors.
UCSD is a world-renowned research institution. The Laboratory of Nanobiomaterials, Bioprinting, and Tissue Engineering at UCSD directed by Prof. Shaochen Chen leads the field for cutting-edge research in 3D bioprinting and biomaterials for tissue engineering and regenerative medicine applications. The group not only investigates the fundamental scientific issues, such as cell interactions with micro and nano-environments, biomaterials science, and biomechanics, but also solves the technological and translational issues associated with tissue/organ repair and regeneration. Bioprinted heart, liver, nerve, spinal cord, and brain tumor tissues have been successfully developed by the Chen group. Press and interviews about their work have appeared in NIH Director’s Blog, NIH Research Matters, NSF News, The Washington Post, The Wall Street Journal, Forbes, etc.